The DNA methyltransferase (DNMT) inhibitors azacytidine and decitabine are the most
successful epigenetic drugs to date and are still the most widely used as epigenetic …

The pharmacological inhibition of DNA methyltransferases provides novel opportunities for
the therapy of human cancers. Several Phase III trials of DNA methyltransferase inhibitors …

DNA methylation is a mammalian epigenetic mark that participates to define where and
when genes are expressed, both in normal cells and in the context of diseases. Like other …

Although chemotherapy is considered the mainstay of cancer therapy, unfortunate side
effects of chemotherapy create a continuous demand for developing other novel and specific …

Epimutations, such as the hypermethylation and epigenetic silencing of tumor suppressor
genes, play a role in the etiology of human cancers. In contrast to DNA mutations, which are …

DNA methylation plays a pivotal role in the etiology of cancer by mediating epigenetic
silencing of cancer-related genes. Since the relationship between aberrant DNA methylation …

The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

There is overwhelming evidence that DNA methylation patterns are altered in cancer.
Methylation of CG-rich islands in regulatory regions of genes marks them for transcriptional …

One of the hallmarks of cancer is aberrant DNA methylation, which is associated with
abnormal gene expression. Both hypermethylation and silencing of tumour suppressor …

Methylation of DNA at 5-position of cytosine, catalyzed by DNA methyltransferases, is the
predominant epigenetic modification in mammals. Aberrations in methylation play a causal …